[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,070
  • Shares Outstanding, K 8,611
  • Annual Sales, $ 0 K
  • Annual Income, $ -34,770 K
  • EBIT $ -40 M
  • EBITDA $ -40 M
  • 60-Month Beta 1.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.54

Options Overview Details

View History
  • Implied Volatility 127.15% (-42.30%)
  • Historical Volatility 158.53%
  • IV Percentile 41%
  • IV Rank 11.10%
  • IV High 633.69% on 12/19/25
  • IV Low 63.91% on 07/10/25
  • Expected Move (DTE 22) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 152
  • Volume Avg (30-Day) 71
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 3,214
  • Open Int (30-Day) 2,865
  • Expected Range 1.7700 to 1.7700

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.04
  • Number of Estimates 2
  • High Estimate $-0.98
  • Low Estimate $-1.10
  • Prior Year $-1.05
  • Growth Rate Est. (year over year) +0.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7000 +4.12%
on 06/25/26
5.3000 -66.60%
on 05/29/26
-3.1900 (-64.31%)
since 05/22/26
3-Month
1.7000 +4.12%
on 06/25/26
6.2800 -71.82%
on 04/20/26
-3.6500 (-67.34%)
since 03/25/26
52-Week
1.7000 +4.12%
on 06/25/26
19.3500 -90.85%
on 10/09/25
-11.1570 (-86.31%)
since 06/25/25

Most Recent Stories

More News
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

ATOS : 1.7700 (+1.14%)
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

ATOS : 1.7700 (+1.14%)
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant Concentrations

ATOS : 1.7700 (+1.14%)
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) research

ATOS : 1.7700 (+1.14%)
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer

Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY Trials

ATOS : 1.7700 (+1.14%)
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

SEATTLE , May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other...

ATOS : 1.7700 (+1.14%)
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women

SEATTLE , May 6, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Atossa or the Company) (Nasdaq: ATOS), a clinical-stage biopharmaceutical company focused on developing novel therapies targeting...

ATOS : 1.7700 (+1.14%)
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome

Designation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atossa for a Priority Review Voucher award upon approval

ATOS : 1.7700 (+1.14%)
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

SEATTLE , March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other...

ATOS : 1.7700 (+1.14%)
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. bring deep expertise across oncology, rare diseases, and global clinical development to support advancement of Atossa's pipeline

ATOS : 1.7700 (+1.14%)

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

3rd Resistance Point 1.8800
2nd Resistance Point 1.8300
1st Resistance Point 1.8000
Last Price 1.7700
1st Support Level 1.7200
2nd Support Level 1.6700
3rd Support Level 1.6400

See More

52-Week High 19.3500
Fibonacci 61.8% 12.6077
Fibonacci 50% 10.5250
Fibonacci 38.2% 8.4423
Last Price 1.7700
52-Week Low 1.7000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.